Background: Adipocyte fatty acid-binding protein (AFABP) was recently introduced as a novel adipokine playing an important role in glucose homeostasis. In this study, we investigated the relationship between serum AFABP levels and metabolic, as well as cardiovascular parameters, in the self-contained population of Sorbs. Furthermore, we conducted a genome-wide association study on serum AFABP concentrations in the Sorbs and we separately analyzed the effects of two common variants in the FABP4 gene on AFABP serum concentration. Methods: Serum AFABP concentrations were quantified by enzyme-linked immunosorbent assay and correlated with metabolic and cardiovascular parameters, as well as inflammatory markers and renal function, in 868 well-characterized non-diabetic Sorbs from Germany. Results: Median AFABP serum concentrations were 1.5-fold higher in female subjects (23.03 mg l À1 ) as compared to male subjects (15.86 mg l À1 ). Waist-to-height ratio and glomerular filtration rate were independently associated with AFABP concentrations in multiple regression analysis in both female and male subjects. The genome-wide scan for association of single-nucleotide polymorphisms with serum AFABP levels in the Sorbs revealed 39 loci reaching P-values o10 À4 . Two single-nucleotide polymorphisms, rs16909187 and rs10808846, representing common genetic variation in FABP4 did not show any effect on serum AFABP concentrations in our study cohort. Conclusion: AFABP serum concentrations are determined by parameters of fat distribution, renal function and gender.
Introduction
The incidence of obesity and associated disorders including type 2 diabetes mellitus, dyslipidemia and hypertension is rapidly increasing worldwide. In recent years, evidence has accumulated that adipose tissue secretes various proteins, the so-called adipokines. These adipokines act as insulinsensitizing protein or induce insulin resistance (IR), and are likely to contribute to the increased metabolic and cardiovascular risk in obesity. 1, 2 Recently, adipocyte fatty acid-binding protein (AFABP, also known as aP2 and FABP4) has been introduced as a novel adipokine, which is secreted from mature adipocytes into the blood. 3 AFABP serum levels were significantly increased in overweight and obese subjects as compared with lean controls and correlated positively with waist circumference, blood pressure and IR. 3 Elevated concentrations of circulating AFABP independently predicted the risk of developing a metabolic syndrome during a follow-up of 5 years in a study with 495 non-diabetic Chinese adults. 4 Furthermore, subjects with higher AFABP baseline serum levels showed a pronounced cardiometabolic risk profile. 4 High baseline AFABP serum levels also predicted the risk over 10 years to develop type 2 diabetes mellitus independent of obesity, IR and glycemic indices. 5 Moreover, serum AFABP levels positively correlated with carotid intima-media thickness (IMT) and the association remained significant in women after controlling for age, hypertension, dyslipidemia, hyperglycemia and C-reactive protein (CRP). 6 Interestingly, studies in animals [7] [8] [9] [10] [11] and humans 12 suggested that AFABP is not only independently related to metabolic and cardiovascular disease, but directly promotes these conditions. These results indicate that AFABP might have a central role in the development of the metabolic syndrome and related cardiovascular disease.
To date, no study with sufficient statistical power has included gender, renal function, metabolic and vascular risk markers combined in its analysis of AFABP serum concentrations. Moreover, genetic factors, as well as gene-environmental interactions, might contribute to variations of serum AFABP levels. To address these issues, we determined circulating AFABP concentrations in 868 extensively phenotyped non-diabetic subjects in the self-contained population of Sorbs and correlated levels of this adipokine to clinical and biochemical measures of vascular and renal function, indices of IR and insulin secretion, lipid metabolism, as well as inflammation. Furthermore, we conducted a genome-wide association study for serum AFABP concentrations. Moreover, we examined whether two common variants in FABP4 might explain the variability in AFABP serum concentrations in our study population.
Subjects and methods

Subjects
All subjects are part of a sample from an extensively phenotyped self-contained population from Eastern Germany, the Sorbs as described in more detail recently. 13, 14 The Sorbs are of Slavonic origin, and during the past 1100 years, they lived as a well-defined ethnic minority among the Germanic majority. At present, 1052 Sorbs are enrolled in the study. To exclude any secondary effects, associations with glucose and insulin levels were assessed only in the subgroup of non-diabetic subjects (N ¼ 868, definition according to the American Diabetes Association criteria 15 ).
Anthropometric measurements
Phenotyping included collection of anthropometric data (weight, height, body mass index (BMI), waist-to-hip-ratio (WHR), waist-to-height-ratio, body impedance analysis) and a 75-g oral glucose tolerance test. Furthermore, homeostasis model assessment of IR, Stumvoll-index and quantitative insulin sensitivity check index were calculated as described previously. [16] [17] [18] Renal function was assessed as glomerular filtration rate (GFR) estimated by Chronic Kidney Disease Epidemiology Collaboration equation. 19 Ultrasound sensor (10 MHz; GE Healthcare Inc., Munich, Germany) was used to measure the IMT of the common carotid arteries. After three measurements, IMT values at each side were averaged. Body impedance analysis was performed with body impedance analysis-2000-S (Data Input GmbH, Darmstadt, Germany) and evaluated with the software Nutri3 (Data Input GmbH). The study was approved by the local Ethics Committee and all subjects gave written informed consent before taking part in the study. 40.80 and minor allele frequency 40.05). The SNP genotypes were filtered from the previously generated 500K Affymetrix GeneChip and the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix Inc.) data set in the Sorbs. 13, 14 Statistical analysis PASW software version 18.0.1 (SPSS, Chicago, IL, USA) was used in all statistical analyses. Before statistical analysis, nonnormally distributed parameters were logarithmically transformed to approximate a normal distribution. Differences between male and female subjects were assessed by MannWhitney U-test. Correlations were performed using the Spearman's rank correlation method. To adjust the effects of covariates and identify independent relationships, multivariate linear regression analyses were performed. A P-value Predictors of AFABP serum levels A Tönjes et al of o0.05 was considered as statistically significant in all analyses.
The calculation of minor allele frequencies, HardyWeinberg equilibrium and missing rates per SNP was performed with PLINK. 20 Genetic associations were assessed in non-diabetic subjects (N ¼ 800) by linear regression using PLINK (http://pngu.mgh.harvard.edu/purcell/plink/). 20 All analyses were performed in the additive mode of inheritance with adjustment for age, gender and BMI, and for relatedness by using genomic control (l ¼ 1.037). Linkage disequilibrium metrics were calculated in Haploview 4.1.
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Results
Study subjects
Baseline subject characteristics are summarized in AFABP serum levels correlate with parameters of metabolic syndrome in univariate and multivariate regression analyses In univariate analyses, serum AFABP levels were significantly associated with age, blood pressure, parameters of obesity (BMI, fat mass, waist circumferences, hip circumferences, WHR, WtHR), metabolic parameters (fasting glucose, fasting insulin, homeostasis model assessment-IR, Stumvoll-index, quantitative insulin sensitivity check index, cholesterol, TG), as well as with renal function (creatinine, GFR), IMT and CRP in both female and male subjects ( Table 2) .
Multiple linear regression analysis revealed that obesity assessed by WtHR and renal function assessed by GFR Predictors of AFABP serum levels A Tönjes et al remained independently associated with circulating AFABP levels after adjustment for age, DBP, Stumvoll index, cholesterol, TG, IMT and CRP (Po0.001) in both female and male subjects ( Table 3 ). The associations between AFABP serum levels, GFR and BMI are further depicted in Figure 1 . In addition, Stumvoll-index remained independently and negatively associated with AFABP in female subjects, whereas in men, TG and CRP were independent and positive predictors of circulating AFABP (Table 3) .
Status of parity and AFABP serum levels Of the 531 women in the analysis, 99 had no birth, 30 had one birth, 104 two births, 146 three births, 83 four births, 55 five and more births, whereas 14 female subjects did not provide details on parity status. Median serum AFABP levels were significantly different in 517 women according to their parity status (Po0.001) (Figure 2 ). However, when this Predictors of AFABP serum levels A Tönjes et al analysis was adjusted for all parameters, which were independently associated with serum AFABP in female subjects according to Table 3 (WtHR, Stumvoll-index, GFR), this difference did not persist (P40.05; data not shown).
Genome-wide association study for AFABP serum concentrations The genome-wide scan for association of SNPs with serum AFABP levels in the Sorbs revealed 39 loci reaching P-values o10 À4 (Table 4 ). Analyses were adjusted by age, gender and BMI. P-values did not reach genome-wide level of significance.
Lack of significant effects of rs16909187 and rs10808846 on AFABP serum levels In non-diabetic subjects, the variants rs16909187 and rs10808846 covering all known common genetic variation in the AFABP gene did not show significant association with AFABP serum levels in the analyses adjusted by age, gender and BMI (rs16909187: P ¼ 0.606 and rs10808846: P ¼ 0.707). Abbreviations: A1, minor allele; AFABP, adipocyte fatty acid-binding protein; CHR, chromosome; SNP, single-nucleotide polymorphism. Effect directions are standardized to the minor allele. Genes with a maximum distance of 200 kb to the SNP are provided. All SNP with P-values o10 À4 are presented.
Analyses were adjusted by age, gender and BMI. P-values are adjusted for genomic control.
Predictors of AFABP serum levels A Tönjes et al
Results did not change significantly when GFR was included as an additional covariate (rs16909187: P ¼ 0.568 and rs10808846: P ¼ 0.898).
Discussion
In this study, we show in a clinically well-characterized cohort that markers of obesity and renal dysfunction independently predict serum AFABP levels in an additive manner. Furthermore, gender is independently related to circulating levels of the adipokine. In addition, two tagging SNPs covering FABP4 are not associated with AFABP serum concentrations. However, genetic modulators of serum AFABP concentrations are likely to exist such as for other adipokines. 22 So far, a genome-wide association study on circulation AFABP levels has not been performed. In our study, we now provide a list of potential loci affecting AFABP secretion. However, it needs to be emphasized that the value (10
À4
) for genetic association is not at the genome-wide significance level and that our findings only hint to a genetic association. Further replication studies are required to validate these candidates and our data should be a stimulus for further replication in independent cohorts and metaanalyses. Robustly replicated loci would provide further insights into the complex pathophysiology of AFABP secretion and would be a valuable basis for functional analyses of the identified genes.
Our findings that markers of obesity, including WtHR (Table 3) , BMI, WHR, hip circumference, waist circumferences and percent body fat (data not shown), are independently associated with AFABP are consistent with recent data. Thus, Xu et al. 4 demonstrate a direct independent correlation between baseline age-and gender-adjusted serum AFABP concentrations and BMI after 5-year follow-up in 495 non-diabetic adults. Furthermore, AFABP serum levels are associated with BMI in 67 non-obese and healthy subjects and 71 patients with the metabolic syndrome. 23 Moreover, weight loss by gastric banding leads to a significant decrease in circulating AFABP in 33 morbidly obese patients and AFABP levels are significantly correlated with BMI before and 6 months after surgery. 24 Taking these data into consideration, it is tempting to speculate that AFABP production increases in hyperplastic and hypertrophic adipose tissue during weight gain similar to the regulation of the adipokine leptin. In accordance with this hypothesis, serum AFABP levels closely and positively correlate with AFABP expression in adipose tissue. 4 In this study, we present evidence that renal dysfunction is independently associated with higher AFABP serum levels. These results are in accordance with the hypothesis that renal elimination is a major route by which physiological AFABP serum levels are maintained similar to other adipokines. 25, 26 Furthermore, our results are in agreement with a recent pilot study from our group showing significantly increased serum AFABP levels in hemodialysis patients. 27 Interestingly, markers of obesity and renal function are both independently associated with AFABP serum concentrations in this study. These findings are reminiscent of data showing an additive effect of body fat mass and impaired renal function on serum leptin levels. 28 Furthermore, our current results indicate that the so far underappreciated role of kidney function in AFABP physiology should be taken into account in all analyses concerning physiology of this adipokine. Moreover, the complex interaction between increased AFABP secretion by adipose tissue and impaired elimination of AFABP by the kidneys needs to be elucidated in more detail in additional studies. In this study, AFABP serum levels are significantly higher in female as compared to male subjects in agreement with recent findings. 6 Furthermore, insulin sensitivity is an independent predictor of circulating AFABP exclusively in women, whereas TG and CRP independently predict AFABP serum concentrations only in men. Interestingly, a genderdependent regulation has also been demonstrated for other adipokines, including adiponectin, 29 leptin 30,31 and vaspin. 32 For leptin and adiponectin, an inhibitory effect of androgens on expression of both adipokines could be established. Thus, castrated mice show higher adiponectin levels and testosterone treatment significantly reduces concentrations of this fat-secreted factor. 29 In agreement with these results, testosterone replacement therapy in hypogonadal men reduces adiponectin and leptin serum levels. 33 Furthermore, there is a transient drop in adiponectin concentrations during male puberty associated with an increase of testosterone levels in boys. 34 It needs to be determined in future studies whether a similar mechanism leads to decreased levels of AFABP in men. Besides this gender-specific difference, AFABP serum levels are upregulated with increasing parity number in our population. However, this difference does not persist after adjustment for markers of obesity, insulin sensitivity and renal function, suggesting that it is mainly driven by these factors. It is interesting to note in this context that an association of parity and visceral fat mass has been demonstrated recently. 35 In our study, serum AFABP levels are positively associated with IMT in both genders. However, this association is lost in multivariate analysis adjusting for markers of obesity and renal function. In contrast to our results, Yeung et al. 6 demonstrate an independent association between AFABP and carotid IMT in non-diabetic and diabetic women. It is worth noting in this context that the results presented by Yeung et al. 6 have not been adjusted for renal function. It needs to be emphasized that it is well possible that AFABP is a cardiovascular risk factor in cohort studies as metabolic and cardiovascular risk markers determined in our study significantly overlap. Furthermore, the sensitivity of the cardiovascular risk parameters assessed in our study might be significantly lower as compared to the metabolic factors. As shown for other adipokines such as adiponectin, 22, 36 genetic factors are likely to contribute to variations of AFABP Predictors of AFABP serum levels A Tönjes et al serum levels. The most obvious candidate gene is FABP4 on chromosome 8 encoding AFABP. Two tagging SNPs covering the common genetic variation within the AFABP locus do not show any significant effects on AFABP serum concentrations in our study. However, based on the limited sample size, a lack of power should be taken into account. In the GWAS, we do not detect any signals reaching the genomewide level of significance. Further studies in independent cohorts and meta-analyses of larger samples are required to identify genetic factors contributing to variance of AFABP serum levels. In summary, our results suggest that gender, markers of obesity and renal function are independent predictors of AFABP serum levels. We are unable to establish an independent association between circulating AFABP on one hand and vascular disease as well as common variants in FABP4 on the other hand. It remains unclear whether circulating AFABP is just a bystander when different facets of the metabolic syndrome are present or whether the adipokine significantly influences these conditions. Therefore, further studies have to elucidate the physiological role of elevated circulating AFABP in obesity and the metabolic syndrome.
